– Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – – Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly Diagnosed First-Line AML Patients Expected in Q1 2026 – – $44.3 Million in Cash and Cash Equivalents as of September 30, 2025; Additional$29.1 Million in Proceeds Received in October 2025 through Warrant Exercises – NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ o ...